AGEN
Agenus Inc.
AGEN trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AGEN overall, supported by lower modeled downside and stronger fundamentals.
AGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
AGEN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.1x | $1.52 | -78% |
| Fair | 3.1x | $2.20 | -68% |
| Current | 9.7x | $6.87 | — |
| Expensive | 15x | $10.89 | +58% |
Historical ranges are pointers, not guarantees.
AGEN's PE is 9.7x, but its earnings don't support one, so it isn't a reliable read right now.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over AGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
AGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect AGEN's earnings and revenue to decline, though with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.71 | +$2.75 |
| Q2 2026 | $2.63 | +$9.69 |
| Q1 2026 | $1.64 | +$10.22 |
| Q4 2025 | -$0.41 | +$10.18 |
| Q3 2022 | -$14.52 | -$12.16 |
| Q2 2022 | $3.34 | +$25.32 |
| Q1 2022 | -$0.59 | +$19.63 |
| Q4 2021 | -$2.16 | +$18.84 |
AGEN has returned to profit: it earned $0.71 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over AGEN on earnings, with more consistent year-over-year improvement.
AGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $31.5M | +4.1% |
| Q2 2026 | $34.5M | +34% |
| Q1 2026 | $33.7M | +40% |
| Q4 2025 | $34.2M | +27% |
| Q3 2025 | $30.2M | +20% |
| Q2 2025 | $25.7M | +9.3% |
| Q1 2025 | $24.1M | -14% |
| Q4 2024 | $26.8M | -68% |
AGEN's revenue has grown year over year for six quarters in a row: $31M last quarter, up 4.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 36% | +51 points |
| Q2 2026 | 33% | +98 points |
| Q1 2026 | 45% | +100 points |
| Q4 2025 | 42% | +139 points |
| Q3 2025 | -15% | +110 points |
| Q2 2025 | -65% | +63 points |
| Q1 2025 | -55% | +62 points |
| Q4 2024 | -96% | -92 points |
AGEN has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AGEN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
AGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.1M | -$5.4M |
| Q2 2026 | -$31.2M | -$11M |
| Q1 2026 | -$36M | -$10.3M |
| Q4 2025 | -$16.6M | +$12.1M |
| Q3 2025 | -$14.7M | +$38.6M |
| Q2 2025 | -$20.2M | +$18.4M |
| Q1 2025 | -$25.6M | +$12.6M |
| Q4 2024 | -$28.7M | +$11.9M |
AGEN has burned cash in almost every quarter: −$104M over the past year, against −$89M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +101% | +41.9M shares |
| 1 year | +196% | +55.2M shares |
| 3 years | +795% | +74M shares |
AGEN has 83M diluted shares, up 196% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | $42,000 |
| Q3 2023 | $328,000 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.3x | Net Cash |
| Q2 2022 | -3.6x | Net Cash |
| Q1 2022 | -6.1x | Net Cash |
| Q4 2021 | -8.6x | Net Cash |
| Q3 2021 | -3.7x | Net Cash |
AGEN has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
AGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 22.9 | Neutral |
AGEN's weekly RSI is 54 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AGEN PE vs Healthcare Sector
| Metric | AGEN | Sector median | Relative |
|---|---|---|---|
| PE | 9.7x | 26x | 62% below |
| PE % | 64 | 29 | 35 pts above |
AGEN has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.22 | 4.8% below |
| 20 week MA | $6.81 | 0.9% above |
| 50 week MA | $4.78 | 44% above |
| 100 week MA | $4.30 | 60% above |
| 200 week MA | $11.7 | 41% below |
AGEN's trend is mixed: it's above three of its five weekly moving averages, and 41% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AGEN on trend strength, trading above more of its moving averages.
AGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $82.8 | $67.7 | -18% |
| 2021 | $67.7 | $71.6 | +5.8% |
| 2022 | $71.6 | $49.1 | -32% |
| 2023 | $49.1 | $16.6 | -66% |
| 2024 | $16.6 | $2.75 | -83% |
| 2025 | $2.75 | $3.31 | +20% |
| 2026 YTD | $3.31 | $6.87 | +108% |
AGEN has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.